ERYTech: Pfizer’s inotuzumab gets breakthrough therapy designation in ALL. Read-across for Erytech

BUY, Fair Value EUR42 (+42%)
News published on October Tuesday 20, 2015
Share on

Pfizer announced it has received a Breakthrough Therapy Designation for inotuzumab ozogamicin following its phase III results as a monotherapy for adults suffering from ALL. We recognise that this antibody drug conjugate should be a new competitor for GRASPA, but we think the Street should not overestimate its ability to be a nuisance.


For more information, please contact marketing@bryangarnier.com  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities